Zacks Investment Research upgraded shares of Invacare (NYSE:IVC) from a sell rating to a hold rating in a research report report published on Thursday morning.

According to Zacks, “Invacare Corporation is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the company designs, manufactures and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The company’s products are important parts of care for people with a wide range of challenges, from those who are active and involved in work or school each day and may need additional mobility or respiratory support, to those who are cared for in residential care settings, at home and in rehabilitation centers. “

Several other research analysts have also commented on IVC. ValuEngine raised shares of Invacare from a buy rating to a strong-buy rating in a report on Friday, June 8th. TheStreet lowered shares of Invacare from a c rating to a d+ rating in a report on Friday, August 10th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $21.50.

NYSE IVC opened at $16.30 on Thursday. Invacare has a one year low of $13.95 and a one year high of $20.00. The company has a quick ratio of 1.41, a current ratio of 2.10 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $533.42 million, a PE ratio of -8.45 and a beta of 2.32.

Invacare (NYSE:IVC) last posted its quarterly earnings results on Tuesday, August 7th. The health services provider reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.11). Invacare had a negative net margin of 6.80% and a negative return on equity of 12.52%. The business had revenue of $246.15 million during the quarter, compared to analyst estimates of $247.90 million. equities analysts forecast that Invacare will post -1.28 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 26th. Stockholders of record on Friday, October 12th will be issued a $0.0125 dividend. This represents a $0.05 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, October 11th. Invacare’s dividend payout ratio (DPR) is presently -2.59%.

In other news, SVP Dean J. Childers sold 7,000 shares of Invacare stock in a transaction dated Friday, June 29th. The shares were sold at an average price of $18.71, for a total value of $130,970.00. Following the completion of the transaction, the senior vice president now directly owns 34,631 shares of the company’s stock, valued at approximately $647,946.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 2.10% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of Montreal Can boosted its stake in Invacare by 7,076.0% during the 2nd quarter. Bank of Montreal Can now owns 7,463 shares of the health services provider’s stock valued at $139,000 after purchasing an additional 7,359 shares during the period. Piedmont Investment Advisors LLC acquired a new position in Invacare during the 2nd quarter valued at about $144,000. Contravisory Investment Management Inc. acquired a new position in Invacare during the 2nd quarter valued at about $159,000. Brown Advisory Inc. acquired a new position in Invacare during the 2nd quarter valued at about $207,000. Finally, SG Americas Securities LLC acquired a new position in Invacare during the 2nd quarter valued at about $234,000.

About Invacare

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company operates through four segments: North America/Home Medical Equipment, Institutional Products Group, Europe, and the Asia/Pacific.

Read More: Google Finance

Get a free copy of the Zacks research report on Invacare (IVC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with's FREE daily email newsletter.